| Bioactivity | Cetagliptin is an orally active inhibitor for dipeptidyl peptidase 4 (DPP-4) and CYP2D6 (IC50 of 6 µM). Cetagliptin is a substrate for P-glycoprotein. Cetagliptin reduces the GLP-1 degradation, maintains the level of postprandial blood sugar, and can be used in type 2 diabetes mellitus research[1]. |
| CAS | 2243737-33-7 |
| Formula | C18H21F6N4O5P |
| Molar Mass | 518.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhou C, et al., Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2024 Mar 11;15:1359407. [2]. Lu J, et al., In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers. Xenobiotica. 2021 Oct;51(10):1122-1131. |
Cetagliptin
CAS: 2243737-33-7 F: C18H21F6N4O5P W: 518.35
Cetagliptin is an orally active inhibitor for dipeptidyl peptidase 4 (DPP-4) and CYP2D6 (IC50 of 6 µM). Cetagliptin is
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.